Aeolus' AEOL 10150 Supresses Overexpression of 31 Hypoxia-Related Genes Caused by Radiation Exposure
October 17, 2012 08:55 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 17, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
AEOL 10150 improves tissue oxygenation and reduces hypoxia-associated...
Aeolus Pharmaceuticals Provides Positive Update on FDA Meeting
September 06, 2012 08:05 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Sep 6, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2012 Financial Results
August 14, 2012 17:02 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Aug 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$1.4 million in revenue for third quarter 2012; $5.9...
Aeolus Pharmaceuticals Announces AEOL 10150 Diminishes Oxidative Stress and Nerve Damage Following Exposure to Nerve Agent
July 30, 2012 08:48 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jul 30, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces AEOL 10150 Reduces Lung Damage After Neupogen(R) Treatment Following Radiation Exposure
June 01, 2012 08:58 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jun 1, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2012 Financial Results
May 14, 2012 19:48 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - May 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$2.2 million in revenue for second quarter 2012; $4.4...
BARDA Exercises $9.1 Million in Contract Options With Aeolus
April 16, 2012 08:41 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 16, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
BARDA Delivers Notice of Intent to Exercise Additional Contract Options With Aeolus Worth $9.1 Million
April 09, 2012 04:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 9, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
BARDA notice of intent to exercise options valued at...
Aeolus Pharmaceuticals Announces Date and Time for Barda Contract and Corporate Update Conference Call
April 05, 2012 15:39 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 5, 2012) - Aeolus Pharmaceuticals (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus to Present at Roth Capital Partners' 24th Annual Growth Stock Conference
March 13, 2012 06:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Mar 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...